Please use this identifier to cite or link to this item:
Título : Inflammaging, metabolic syndrome and melatonin : a call for treatment studies
Autor : Cardinali, Daniel Pedro 
Hardeland, Rüdiger 
Fecha de publicación : 2017
Editorial : Karger Publishers
Cita : Cardinali D. P., Hardeland, R. Inflammaging, metabolic syndrome and melatonin : a call for treatment studies [en línea]. Preprint del documento publicado en Neuroendocrinology. 2017, 104 (4). doi:10.1159/000446543. Disponible en:
Resumen : Abstract: The metabolic syndrome (MS) is a collection of risk factors for cardiovascular disease, including obesity, hypertension, hyperinsulinemia, glucose intolerance and dyslipidemia. MS is associated with low-grade inflammation of the white adipose tissue, which can subsequently lead to insulin resistance, impaired glucose tolerance and diabetes. Adipocytes secrete proinflammatory cytokines as well as leptin and trigger a vicious circle which leads to additional weight gain largely as fat. The imbalance between inflammatory and anti-inflammatory signals is crucial to aging. Healthy aging can benefit from melatonin, a compound known to possess direct and indirect antioxidant properties, to have a significant protective effect on mitochondrial function, to enhance circadian rhythm amplitudes, to modulate the immune system and to exhibit neuroprotective actions. Melatonin levels decrease in the course of senescence and are more strongly reduced in diseases related to insulin resistance. This short review article analyzes the multiple protective actions of melatonin that are relevant to the attenuation of inflammatory responses and progression of inflammaging and how melatonin is effective to curtail MS in animal models of hyperadiposity. The clinical data supporting the possible therapeutical use of melatonin in human MS are also reviewed. Since attention has been focused on the development of potent melatonin analogs with prolonged effects (ramelteon, agomelatine, tasimelteon, piromelatine) and in clinical trials these analogs were administered in doses considerably higher than those usually employed for melatonin, clinical trials on melatonin in the range of 50-100 mg/day are needed to further assess its therapeutic value in MS.
ISSN : 1423-0194 (online)
0028-3835 (impreso)
Disciplina: MEDICINA
DOI: 10.1159/000446543
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
inflammaging-metabolic-syndrome-melatonin.pdf1,39 MBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Aug 11, 2022


checked on Aug 11, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons